Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
International Journal of Molecular Sciences|August 16, 2019
TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate CancerYohei Sekino, Xiangrui Han, Takafumi Kawaguchi, et al.
Cancer Medicine|August 24, 2017
Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinomaHiroyuki Kitano, Yasuhiko Kitadai, Jun Teishima, et al.
Urologic Oncology|May 21, 2020
Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancerYohei Sekino, Xiangrui Han, Takashi Babasaki, et al.
Biomedicines|August 27, 2021
HOXB5 Overexpression Is Associated with Neuroendocrine Differentiation and Poor Prognosis in Prostate CancerYohei Sekino, Quoc Thang Pham, Kohei Kobatake, et al.
Molecular and Clinical Oncology|April 28, 2020
Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapyJun Teishima, Daiki Murata, Shogo Inoue, et al.
International Urology and Nephrology|September 26, 2019
Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancerKenichiro Fukuoka, Jun Teishima, Hirotaka Nagamatsu, et al.
Japanese Journal of Clinical Oncology|August 8, 2018
Preoperative risk classification using neutrophil-lymphocyte ratio and hydronephrosis for upper tract urothelial carcinomaYuki Kohada, Tetsutaro Hayashi, Keisuke Goto, et al.
Japanese Journal of Clinical Oncology|February 27, 2020
Impact of radiological morphology of clinical T1 renal cell carcinoma on the prediction of upstaging to pathological T3Jun Teishima, Tetsutaro Hayashi, Hiroyuki Kitano, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 11, 2020
Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitorsJun Teishima, Shogo Inoue, Tetsutaro Hayashi, et al.
BMC Cancer|October 12, 2017
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trialKouji Izumi, Atsushi Mizokami, Mikio Namiki, et al.
Pageof 10